Compare NVST & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | IDYA |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 2019 | 2019 |
| Metric | NVST | IDYA |
|---|---|---|
| Price | $21.79 | $34.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $21.17 | ★ $49.18 |
| AVG Volume (30 Days) | ★ 2.3M | 948.9K |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $2,621,800,000.00 | $214,834,000.00 |
| Revenue This Year | $7.42 | $2,662.86 |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $255.66 | ★ N/A |
| Revenue Growth | 4.73 | ★ 5377.66 |
| 52 Week Low | $14.22 | $13.45 |
| 52 Week High | $22.68 | $37.08 |
| Indicator | NVST | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 55.45 |
| Support Level | $21.69 | $33.11 |
| Resistance Level | $22.67 | $34.45 |
| Average True Range (ATR) | 0.60 | 1.17 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 68.53 | 62.07 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.